## 3 Results
### Primary Outcome of the Intervention on Probing Pocket Depth (PD) Reduction  
All seven studies assessed the PD at baseline and at the endpoint. The frequency of follow-up assessments varied from one to four follow-up appointments. Re-evaluation took place after 10 days, 4 weeks, or 12 weeks. Studies with the same follow-up period are compared in Table 3. \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Study** & **NSAID** & **Dose** & **Duration** & **Max. Dose/d** \\ \hline \multicolumn{5}{c}{Early follow-up: 7 d–4 wks} \\ \hline [PERSON] et al., 2008 & Etoricoxib & 120 mg & 1x/d, 7 d & 120 mg (max 8 d) \\ [PERSON] et al., 2010 & Meloxicam & 7.5 mg & 1x/d, 10 d & 15 mg \\ [PERSON] et al., 2007 & Flurbiprofen & 100 mg & 2x/d, 10 d & 300 mg \\ [PERSON] et al., 2014 & Tenoxicam & 20 mg & 1x/d, 10 d & 40 mg \\ \hline \multicolumn{5}{c}{Late follow-up: 6–12 wks} \\ \hline [PERSON] et al., 2007 & Naproxen Sodium & 275 mg & 1x/d, 6 wks &
\begin{tabular}{c} 600 mg \\ 1250 mg (prescription) \\ \end{tabular} \\ [PERSON] et al., 2003 & Nimesulide & 100 mg & 2x/d, 10 d & 200 mg (max 15 d) \\ Naproxen & 275 mg & 2x/d, 10 d & s.o. \\ [PERSON] et al., 2008 & Celecoxib & 200 mg & 1x/d, 6 mths & 400 mg \\ \hline \hline \end{tabular}
\end{table} 
Table 2: NSAID dose and duration of follow-up in studies included in the quantitative assessment. \begin{table}
\begin{tabular}{c c c c c c} \hline \hline
**Study and Groups** & **Non-NSAID (n)** & **NSAID (n)** & \
\begin{tabular}{c} **\(\Delta\)PD in mm** \\ **Non-NSAID (SD)** \\ \end{tabular} &
\begin{tabular}{c} **\(\Delta\)PD in mm** \\ **NSAID (SD)** \\ \end{tabular} & **Dose (\%)** \\ \hline \multicolumn{5}{c}{10 day-follow-up} \\ \hline [PERSON] et al., 2010 & 20 & 20 & \(-1.30\) (1.42) & \(-1.60\) (1.13) & 50 \\ [PERSON] et al., 2007 & / & / & / & 33.3 \\ smokers & 15 & 14 & \(-0.01\) (0.50) & 0.01 (1.51) & \\ non-smokers & 15 & 14 & \(-0.01\) (0.62) & 0.01 (1.21) & \\ \hline \multicolumn{5}{c}{4 week/30 days-follow-up} \\ \hline [PERSON] et al., 2010 & 20 & 20 & \(-1.90\) (1.48) & \(-2.80\) (1.20) & 50 \\ [PERSON] et al., 2008 & 10 & 10 & \(-2.48\) (0.99) & \(-2.17\) (0.44) & 100 \\ [PERSON] et al., 2014 & 16 & 16 & \(-0.72\) (0.77) & \(-0.72\) (0.64) & 50 \\ \hline \multicolumn{5}{c}{12 week-follow-up} \\ \hline [PERSON] et al., 2003 & 10 & & \(-4.1\) (1.39) & & \\ Nimesulide & & 10 & & \(-3.25\) (1.09) & 50 \\ Naproxen & & 10 & & \(-4.45\) (1.33) & 137.5 \\ [PERSON] et al., 2008 & 47 & 54 & & 50 \\ moderate pockets & & & \(-0.98\) (6.17) & \(-1.14\) (6.76) & \\ deep pockets & & & \(-1.89\) (10.97) & \(-3.27\) (11.46) & \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Probing pocket depth in comparison to non-NSAID and NSAID groups at three different follow-up timepoints. [PERSON] et al. [28] compared 20 patients that received NSAIDs with 20 non-NSAID patients in the control group. The reduction in PD was 1.3 mm in the control group and 1.6 mm in the NSAID group after 10 days, whereas the reduction of PD was much less after 30 days. [PERSON] el. al [29] divided the control and NSAID groups further into smokers and non-smokers, with 15 patients in each non-NSAID group and 14 patients in each NSAID group. Only minimal changes of \(\pm\)0.01 mm were observed, where both the smokers and non-smokers in the non-NSAID group showed an increase in PD of 0.01 mm while the non-smokers in the NSAID group achieved a reduction of 0.01 mm in PD. At four weeks of follow-up, two studies demonstrated only moderate or no differences in the probing pocket depth between the non-NSAID and NSAID groups. [PERSON] et al. [32] showed an average reduction of 2.48 mm (SD 0.99 mm) in the control group compared to 2.17 mm (SD 0.44) in the NSAID group, while [PERSON] et al. [30] found the exact same average reduction of 0.72 mm (SD non-NSAID: 0.77; SD NSAID: 0.64) in both groups. [PERSON] et al. [31] analyzed 3 groups of 10 patients each, either receiving placebo (control group), Nimesulide, or Naproxen (test group).